Iceland-based generic pharmaceuticals company, Actavis has recently acquired 100% of the shares of the Dutch pharmaceutical packing manufacturer PharmaPack International B.V., a specialist in packaging pharmaceutical and biotechnological products.
This recent acquisition now gives Actavis much greater flexibility in tender markets and also allows for minimum order quantities for smaller markets.
CEO at Actavis, Claudio Albrecht explained, “I have known this professional company for a long time and I am very proud that the owners decided to choose Actavis as their new partner. It is obvious that they had other opportunities as well.”
One of the Dutch company’s future roles will be the bulk packaging of pharmaceuticals produced in the Actavis facility in Alathur (India). Another advantage of this packaging centre will be a significant reduction in freight costs.
“Actavis buys a considerable amount of tablets from third-party manufacturers. The lead times are sometimes between six and nine months and therefore much too long. With the acquisition of PharmaPack International we are able to reduce these lead times by more than 50 per cent,” added Albrecht.
Gerard Stevers, Director and owner of PharmaPack International added, “PharmaPack will benefit from the global organisation of Actavis and have great opportunities to grow within this international group…Actavis has very dynamic growth plans for the future and this expansion will have very positive effects for PharmaPack.”
For further information regarding this acquisition, alongside details about the generic pharmaceuticals company, visit www.actavis.com/en.